Detection of vital germ cell tumor cells in short-term cell cultures of primary tumors and of retroperitoneal metastasis ?Clinical implications

1997 ◽  
Vol 25 (2) ◽  
pp. 121-124 ◽  
Author(s):  
T. Otto ◽  
S. Virchow ◽  
C. Fuhrmann ◽  
F. Steinberg ◽  
C. Streffer ◽  
...  
Keyword(s):  
Germ Cell ◽  
Tumor Cells ◽  
Germ Cell Tumor ◽  
Cell Cultures ◽  
Cell Tumor ◽  
Clinical Implications ◽  
Short Term ◽  
Primary Tumors

scholarly journals Differentiation of human germ cell tumor cells in vivo and in vitro.

1992 ◽  
Vol 25 (5) ◽  
pp. 563-576 ◽  
Author(s):  
JUN-ICHI HATA ◽  
JUNICHIRO FUJIMOTO ◽  
EIZABURO ISHII ◽  
AKIHIRO UMEZAWA ◽  
YASUO KOKAI ◽  
...  
Keyword(s):  
Germ Cell ◽  
Tumor Cells ◽  
Germ Cell Tumor ◽  
Cell Tumor ◽  
Human Germ Cell Tumor

Glypican 3 (GPC3) expression in a lethal subgroup of refractory cisplatin-resistant testicular germ cell tumor (TGCT).

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 559-559
Author(s):  
Jad Chahoud ◽  
Miao Zhang ◽  
Song-Chang Lin ◽  
Sue-Hwa Lin ◽  
Shi-Ming Tu
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cell Tumor ◽  
Next Generation Sequencing Data ◽  
High Dose ◽  
Cell Transplant ◽  
Primary Tumors ◽  
Heavily Pretreated ◽  
Somatic Transformation ◽  
Gpc3 Expression

559 Background: The oncofetal protein GPC3 has been tested as a therapy target. Early phase clinical trials established the safety and efficacy of anti-GPC3 chimeric antigen receptor modified T cells in patients with refractory or relapsed GPC3+ hepatocellular carcinoma. In TGCT, GPC3 is preferentially expressed at presentation in certain germ cell histological phenotypes (yolk sac tumor [YST], choriocarcinoma), but not in others (embryonal carcinoma, teratoma, seminoma). The aim of this study is to evaluate GPC3 expression in a lethal subgroup of refractory cisplatin-resistant TGCT. Methods: We retrospectively evaluated 615 patients diagnosed with TGCT from January 2000 to December 2010. We identified patients who died from their TGCT. The histologic makeup of primary tumors, next-generation sequencing data and the clinical course of disease were determined for each patient. We prospectively evaluated GPC3 expression by immunohistochemistry (IHC) using a mouse monoclonal antibody (YP7), on tumor tissue from these patients with lethal, heavily pretreated, cisplatin-resistant TGCT. Results: We identified seven patients with fatal and cisplatin-resistant TGCT, with a median age of 30 (28-50) years and a median number of prior therapies of 5 (2-8), including 3 patients who received high-dose chemotherapy with autologous stem-cell transplant. The prospectively collected samples were from different sites of metastasis: lymph nodes (n = 4), peritoneal carcinomatosis (n = 2), and lung (n = 1). The tissue histology comprised YST (n = 2), YST + choriocarcinoma (n = 1), YST + teratoma (n = 1), teratoma (n = 1), and somatic transformation (n = 2). No consistent genetic aberration was detected. The viable germ cell tumor components comprising YST and choriocarcinoma (n = 4) stained strongly positive in a membranous distribution for GPC3. While samples with teratoma and somatic transformation histology (n = 3) did not stain for GPC3. Conclusions: Potentially lethal, heavily pretreated, cisplatin-resistant viable germ cell tumors have enhanced expression of GPC3. Targeted therapy directed against GPC3 could benefit patients harboring such tumors and further investigation is of value.

Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis

2002 ◽  
Vol 20 (7) ◽  
pp. 1864-1873 ◽  
Author(s):  
Carsten Bokemeyer ◽  
Craig R. Nichols ◽  
Jean-P. Droz ◽  
Hans-J. Schmoll ◽  
Alan Horwich ◽  
...  
Keyword(s):  
Survival Rate ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Germ Cell Tumors ◽  
Treatment Strategies ◽  
Cell Tumor ◽  
Primary Tumor Site ◽  
Primary Tumors ◽  
Platinum Based Chemotherapy

PURPOSE: To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies.PATIENTS AND METHODS: Of an unselected population of 635 consecutive patients treated from 1975 through 1996 at 11 cancer centers, 341 patients (54%) had primary mediastinal EGCT, and 283 patients (45%) had retroperitoneal EGCT. Five hundred twenty-four patients (83%) had a nonseminomatous germ cell tumor (GCT), and 104 patients (16%) had a seminomatous histology.RESULTS: After platinum-based induction chemotherapy with or without secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow-up, 19 months; range, 1 to 178 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow-up, 29 months; range, 1 to 203 months) are alive (P = .0006). In contrast, the overall survival rate for patients with a seminomatous EGCT is 88%, with no difference between patients with mediastinal or retroperitoneal tumor location (median follow-up, 49 months; range, 4 to 193 months; respective 70 months; range, 1 to 211 months). A significantly lower progression-free survival rate was found in seminoma patients treated with initial radiotherapy alone compared with chemotherapy. Nonseminomatous histology, presence of nonpulmonary visceral metastases, primary mediastinal GCT location, and elevated beta-human chorionic gonadotropin were independent prognostic factors for shorter survival. Hematologic malignancies (n = 17) occurred without exception in patients with primary mediastinal nonseminoma. Sixteen patients developed a metachronous testicular cancer despite the use of platinum-based chemotherapy.CONCLUSION: Whereas patients with pure seminomatous EGCT histology have a long-term chance of cure of almost 90% irrespective of the primary tumor site, 45% of patients with mediastinal nonseminomas are alive at 5 years. This outcome is clearly inferior compared with patients with nonseminomatous retroperitoneal primary tumors.

Clinical Impact of Germ Cell Tumor Cells in Apheresis Products of Patients Receiving High-Dose Chemotherapy

2001 ◽  
Vol 19 (12) ◽  
pp. 3029-3036 ◽  
Author(s):  
C. Bokemeyer ◽  
A. J.M. Gillis ◽  
K. Pompe ◽  
F. Mayer ◽  
B. Metzner ◽  
...  
Keyword(s):  
Germ Cell ◽  
Tumor Cells ◽  
Germ Cell Tumor ◽  
Peripheral Blood ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
High Dose ◽  
Placental Alkaline Phosphatase ◽  
Rt Pcr ◽  
Β Hcg

PURPOSE: High-dose chemotherapy (HD-Ctx) followed by autologous peripheral-blood stem-cell (PBSC) transplantation is currently investigated in patients with poor prognosis or relapsed metastatic germ cell tumor (GCTs). This study analyzed the presence and the clinical importance of contaminating tumor cells in PBSC preparations used to support HD-Ctx in GCT patients. PATIENTS AND METHODS: Seven targets for reverse transcription polymerase chain reaction (RT-PCR)-based detection of GCT cells were able to detect seminomatous and different histologic variants of nonseminomatous tumor cells. PBSC preparations from 57 patients were investigated for the presence of contaminating tumor cells using this set of targets, including beta human chorionic gonadotropin (β-hCG), fibronectin (EDB variant), epidermal growth factor receptor (EGFR), CD44 (v8 to 10 variant), germ cell and placental alkaline phosphatase (AP), human endogenous retrovirus type K (ENV and GAG), and XIST. Samples of PBSC preparations from four healthy donors for allogenic transplantations as well as blood specimens from 10 healthy volunteers served as negative controls. RESULTS: Fifty patients (43 first-line and seven second-line Ctx) were assessable. Combining all RT-PCR results, 29 PBSC preparations (58%) were positive for tumor-specific amplification products (HERV-K 0, fibronectin 4, XIST 14, β-hCG 19, AP 19, CD44 24, EGFR 26). Ten (35%) of 29 patients who underwent transplantation with positive PBSC preparations and seven (33%) of 21 patients with negative PBSC preparations have suffered relapse or progression (not significant [ns]). With a median follow-up of 22 months (2 to 66) post–HD-Ctx projected 3-year survival rates are 68% (RT-PCR+) and 58% (RT-PCR−) (ns). None of the 10 control peripheral-blood samples showed positivity for any of the targets studied. CONCLUSION: GCT cells can be detected in more than 50% of PBSC preparations using a RT-PCR approach with multiple targets. Despite the presence of tumor cells, retransplantation of the PBSC products did not effect long-term outcome. Factors such as responsiveness to chemotherapy and tumor mass seem to overcome the importance of potentially re-infused tumor cells.

scholarly journals Yolk Sac Tumor of the Temporal Lobe: Case Report

2015 ◽  
Vol 37 (03) ◽  
pp. 247-251
Author(s):  
Ana Machado ◽  
Ricardo Taipa ◽  
Manuel Pires ◽  
Carla Silva ◽  
Mário Gomes
Keyword(s):  
Germ Cell ◽  
Temporal Lobe ◽  
Germ Cell Tumor ◽  
Germ Cell Tumors ◽  
High Grade Glioma ◽  
Yolk Sac ◽  
Cell Tumor ◽  
Temporal Lobectomy ◽  
Yolk Sac Tumor ◽  
Primary Tumors

AbstractGerm cell tumors of the central nervous system (CNS) are usually located along the midline. Yolk sac tumor is a rare germ cell tumor very uncommonly located outside the midline, and, in such cases, it can be mistaken with other primary tumors. We report a case of a 32-year-old male patient who presented with a right temporal lobe tumor suggestive of a high grade glioma. He was submitted to a right temporal lobectomy with complete tumor removal. The histological exam revealed a germ cell tumor (later confirmed to be a yolk sac tumor). The search for a primary tumor outside of the CNS (including a positron emission tomography scan) was negative, making this a primary temporal lobe yolk sac tumor. The patient was submitted to chemotherapy and radiotherapy, but died 7 months after the surgery.

Sign in / Sign up

Export Citation Format

Share Document